Discovery of a New Function of Ribavirin, a Therapeutic Agent for Chronic Hepatitis C, and Its Molecular Mechanism
July 21(Fri), 2017
A research team lead by Assistant Professor Shinya Satoh and Professor Nobuyuki Kato of the Department of Tumor Virology of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences has discovered a new function of ribavirin, which is one of the therapeutic agents for chronic hepatitis C, and that function is ribavirin’s ability to suppress lipogenesis. Further, the team has clarified the molecular mechanism of this function. Their research results were published in the July 13th issue of the online hepatology journal “Hepatology Communications”.
The acceleration of lipogenesis not only induces replication of the hepatitis C virus (HCV), but also increases risks of fatty liver and liver cancer associated with chronic hepatitis C. Ribavirin can be expected to be a preventive agent for suppressing the pathogenesis of these clinical conditions.
Journal: Hepatology Communications
Title: Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α.
Authors: Shinya Satoh1, Kyoko Mori1, Daichi Onomura1, Youki Ueda1, Hiromichi Dansako1, Masao Honda2, Shuichi Kaneko2, Masanori Ikeda3 and Nobuyuki Kato1
Year of Publication: 2017
Okayama University Silicon Valley Office (OUSVO)
Contact: Mototaka Senda, Ph.D.
- ribavirin, hepatitis C, HCV,